设计要简单：来自 Mesa Biotech 的微流控创业者和早期公司的经验教训。
Designing for simplicity: lessons from Mesa Biotech for microfluidic entrepreneurs and early-stage companies.
机构信息
Emory University School of Medicine, Atlanta, Georgia, USA.
Georgia Clinical and Translational Science Alliance, Atlanta, Georgia, USA.
出版信息
Lab Chip. 2022 Apr 12;22(8):1469-1473. doi: 10.1039/d2lc00081d.
The COVID-19 pandemic has proven the need for point-of-care diagnosis of respiratory diseases and microfluidic technology has risen to the occasion. Mesa Biotech (San Diego, CA) originally developed the Accula platform for the diagnosis of influenza A and B and then extended the platform to SARS-CoV-2. Mesa Biotech has experienced tremendous success, culminating in acquisition by Thermo Fisher for up to $550m USD. The Accula microfluidics platform accomplished the leap from the lab to commercial product through clever design and engineering choices. Through information obtained from interviews with key Mesa Biotech leaders and publicly-available documents, we describe the keys to Mesa's success and how they might inform other lab-on-a-chip companies.
新冠疫情大流行证明了即时诊断呼吸道疾病的必要性，微流控技术应运而生。Mesa Biotech（加利福尼亚州圣地亚哥）最初开发 Accula 平台用于诊断甲型和乙型流感，随后将该平台扩展到 SARS-CoV-2。Mesa Biotech 取得了巨大成功，最终以高达 5.5 亿美元的价格被 Thermo Fisher 收购。Accula 微流控平台通过巧妙的设计和工程选择，实现了从实验室到商业产品的飞跃。通过对 Mesa Biotech 主要领导人的采访和公开文件中获取的信息，我们描述了 Mesa 成功的关键，以及它们如何为其他芯片实验室公司提供信息。
Zotero 插件